We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Saudi FDA Ratchets Up Controls on Device Clinical Trials

Saudi FDA Ratchets Up Controls on Device Clinical Trials

June 5, 2015

Medical devicemakers must now obtain approval from the Saudi Food and Drug Administration before starting clinical investigations in the country, under guidance released May 27.

No investigational device will be cleared from any port of entry before obtaining SFDA approval. However, sponsors may submit a port of entry clearance letter prior to the agency’s completion of the review process.

Applicants must provide a signed agreement with the clinical investigation site and the contract research organization, if applicable, an approval letter from the investigation review board, the clinical investigation plan and the investigator brochure.

The guidance also sets out requirements for labeling and progress reports on investigational devices. Labeling must include the manufacturer’s name and address, the intended use, the residual risks and a cautionary note.

The label and instructions may be in English if the users are likely to be qualified professionals. Instructions for importers and distributors on handling, storage and transportation, however, should be in both English and Arabic, the guidance says.

The guidance also explains the timeframes in which principal investigators and sponsors must submit progress reports on topic such as adverse effects, plan deviations, recalls, withdrawal of approval and premature termination. Companies should send a clinical trial report to the SFDA and reviewing IRBs within six months of the study’s completion or termination.

In the case of emergency deviations, sponsors must notify the SFDA no later than two calendar days after the emergency occurred.

Read the guidance at www.fdanews.com/05-15-SFDA-CIMD.pdf. — Jonathon Shacat

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing